

DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY-NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Peter Irving

UEG Week Copenhagen 2023

Poster

IBD

October 17, 2023

In advanced therapy-naive ulcerative colitis patients who responded to ozanimod after 52 weeks, efficacy was sustained through up to 3 years of continuous treatment regardless of baseline endoscopic disease severity.

KEY POINTS

- Among 82 advanced therapy-naive patients in clinical response at week 52, ozanimod maintained high rates of clinical remission (65.5-76.9%), clinical response (82.8-100%), and corticosteroid-free remission (62.1-76.9%) through week 94 of the open-label extension.
- Baseline endoscopic disease activity (moderate versus severe) did not affect long-term durability, with similar efficacy rates observed in both groups at weeks 46 and 94.
- Symptomatic clinical response and remission were achieved in 100% and approximately 90% of patients by week 5 of the extension and were maintained through week 94.
- This analysis supports ozanimod as a treatment option for patients with ulcerative colitis who have inadequate response to conventional therapies and are considering advanced therapy.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflif.eu/search/d/51c1503e-743b-11ee-b408-0242ac140004>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.